T. Baumert
Hepatology · 2011–2020
A researcher in the Science corpus: 4 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 65 citations into it
- Epidemiology — 54 citations into it
- Immunology — 28 citations into it
- Genetics — 9 citations into it
Whom T. Baumert trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from T. Baumert's perspective
Ordered by how strongly the researchers T. Baumert trusts endorse each paper. Same corpus, a different order for every researcher.
- Silencing of microRNAs in vivo with ‘antagomirs’ (Nature)
- Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA (Science)
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (Hepatology)
- Mechanisms of hepatic stellate cell activation (Nature Reviews Gastroenterology &Hepatology)
- Exploring the full spectrum of macrophage activation (Nature reviews. Immunology)
- Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. (Journal of Clinical Investigation)
- miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. (Cell Metabolism)
- Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis (Proceedings of the National Academy of Sciences of the United States of America)
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. (The Lancet)
- TLR4 links innate immunity and fatty acid-induced insulin resistance. (Journal of Clinical Investigation)
Their papers
- A Human Liver Cell Atlas reveals Heterogeneity and Epithelial Progenitors (2019) — 957 citations
- Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020) — 1,074 citations
- miR-122--a key factor and therapeutic target in liver disease. (2015) — 598 citations
- EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy (2011) — 728 citations